Shares of Ligand Pharmaceuticals (LGND) are up 135% in 2013. Despite this historic rise, the royalty collecting pharmaceutical company has plenty of room to run as it sees more drug approvals and returns cash to shareholders.
From the company's website:
"Ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. We operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders."
New Approval With Pfizer for Menopause
Only subscribers can access this article, which is part of the PRO research library covering 3,575 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: